Glaxosmithkline Pharmaceuticals Ltd.'s consolidated net profit rose five-fold for the quarter ended Dec. 31. 2024.
The biopharma company reported a profit of Rs 230 crore, a 400% year-on-year jump from Rs 46 crore, beating Bloomberg analysts' estimate of Rs 197 crore.
The firm's revenue rose 18% to Rs 949 crore compared to Rs 805 crore in the previous fiscal, exceeding the estimate of Rs 876 crore.
Its earnings before interest, taxes, depreciation and amoritisation increased by 34% to Rs 292 crore, compared to Rs 218 crore in the same period last year. This surpassed the Bloomberg estimate of Rs 250 crore.
Its margin expanded to 30.7% from 27% in the year ago period. This was also more than the estimate of 28.5% from analysts tracked by Bloomberg.
GlaxoSmithKline Pharmaceuticals Q3 Highlights (Consolidated, YoY)
Net profit up to Rs 230 crore versus Rs 46 crore (Bloomberg estimate: Rs 197 crore).
Revenue up 18% to Rs 949 crore versus Rs 805 crore (Bloomberg estimate: Rs 876 crore).
Ebitda up 34% to Rs 292 crore versus Rs 218 crore (Bloomberg estimate: Rs 250 crore).
Margin at 30.7% versus 27% (Bloomberg estimate: 28.5%).
Shares of Glaxosmithkline Pharmaceuticals rose as much as 2.48% during the day to Rs 2,048.30 apiece on the National Stock Exchange. They closed 0.96% higher at Rs 2,018 per share, compared to a 0.44% decline in the benchmark Nifty. The share price has fallen 6.29% on a 12-month basis.
Two of the four analysts tracking the company have a 'buy' rating on the stock, and two suggest a 'hold', according to Bloomberg data. The average of 12-month analysts' price target implies a potential upside of 10.4%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.